Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-11-03

AUTHORS

Yidi Guan, Shilong Jiang, Wenling Ye, Xingcong Ren, Xinluan Wang, Yi Zhang, Mingzhu Yin, Kuansong Wang, Yongguang Tao, JinMing Yang, Dongsheng Cao, Yan Cheng

ABSTRACT

Oncogenic activation of the mTOR signaling pathway occurs frequently in tumor cells and contributes to the devastating features of cancer, including breast cancer. mTOR inhibitors rapalogs are promising anticancer agents in clinical trials; however, rapalogs resistance remains an unresolved clinical challenge. Therefore, understanding the mechanisms by which cells become resistant to rapalogs may guide the development of successful mTOR-targeted cancer therapy. In this study, we found that eEF-2K, which is overexpressed in cancer cells and is required for survival of stressed cells, was involved in the negative-feedback activation of Akt and cytoprotective autophagy induction in breast cancer cells in response to mTOR inhibitors. Therefore, disruption of eEF-2K simultaneously abrogates the two critical resistance signaling pathways, sensitizing breast cancer cells to rapalogs. Importantly, we identified mitoxantrone, an admitted anticancer drug for a wide range of tumors, as a potential inhibitor of eEF-2K via a structure-based virtual screening strategy. We further demonstrated that mitoxantrone binds to eEF-2K and inhibits its activity, and the combination treatment of mitoxantrone and mTOR inhibitor resulted in significant synergistic cytotoxicity in breast cancer. In conclusion, we report that eEF-2K contributes to the activation of resistance signaling pathways of mTOR inhibitor, suggesting a novel strategy to enhance mTOR-targeted cancer therapy through combining mitoxantrone, an eEF-2K inhibitor. More... »

PAGES

948

Journal

TITLE

Cell Death & Disease

ISSUE

11

VOLUME

11

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41419-020-03153-x

DOI

http://dx.doi.org/10.1038/s41419-020-03153-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1132263726

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33144562


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apoptosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Autophagy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Proliferation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Elongation Factor 2 Kinase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Expression Regulation, Neoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice, Nude", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mitoxantrone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-akt", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "TOR Serine-Threonine Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Cells, Cultured", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Xenograft Model Antitumor Assays", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Pharmacy, The Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.452708.c", 
          "name": [
            "Department of Pharmacy, The Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guan", 
        "givenName": "Yidi", 
        "id": "sg:person.07405203535.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07405203535.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacy, The Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.452708.c", 
          "name": [
            "Department of Pharmacy, The Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jiang", 
        "givenName": "Shilong", 
        "id": "sg:person.015312371350.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015312371350.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Xiangya School of Pharmaceutical Sciences, Central South University, 410008, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.216417.7", 
          "name": [
            "Xiangya School of Pharmaceutical Sciences, Central South University, 410008, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ye", 
        "givenName": "Wenling", 
        "id": "sg:person.010006343607.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010006343607.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cancer Biology and Toxicology, Department of Pharmacology, College of Medicine, Markey Cancer Center, University of Kentucky, 40536, Lexington, KY, USA", 
          "id": "http://www.grid.ac/institutes/grid.266539.d", 
          "name": [
            "Department of Cancer Biology and Toxicology, Department of Pharmacology, College of Medicine, Markey Cancer Center, University of Kentucky, 40536, Lexington, KY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ren", 
        "givenName": "Xingcong", 
        "id": "sg:person.01203713300.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203713300.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Translational Medicine R&D Center, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, 518057, Shenzhen, China", 
          "id": "http://www.grid.ac/institutes/grid.458489.c", 
          "name": [
            "Translational Medicine R&D Center, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, 518057, Shenzhen, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Xinluan", 
        "id": "sg:person.0660701641.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660701641.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China", 
          "id": "http://www.grid.ac/institutes/grid.263761.7", 
          "name": [
            "Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Yi", 
        "id": "sg:person.015533713660.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015533713660.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.216417.7", 
          "name": [
            "Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yin", 
        "givenName": "Mingzhu", 
        "id": "sg:person.01266357307.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266357307.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, Xiangya Hospital, Central South University, 410078, Changsha, China", 
          "id": "http://www.grid.ac/institutes/grid.216417.7", 
          "name": [
            "Department of Pathology, Xiangya Hospital, Central South University, 410078, Changsha, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Kuansong", 
        "id": "sg:person.0755563621.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755563621.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Research Institute, School of Basic Medicine, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Central South University, 410008, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.216417.7", 
          "name": [
            "Cancer Research Institute, School of Basic Medicine, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Central South University, 410008, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tao", 
        "givenName": "Yongguang", 
        "id": "sg:person.0644067526.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644067526.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cancer Biology and Toxicology, Department of Pharmacology, College of Medicine, Markey Cancer Center, University of Kentucky, 40536, Lexington, KY, USA", 
          "id": "http://www.grid.ac/institutes/grid.266539.d", 
          "name": [
            "Department of Cancer Biology and Toxicology, Department of Pharmacology, College of Medicine, Markey Cancer Center, University of Kentucky, 40536, Lexington, KY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yang", 
        "givenName": "JinMing", 
        "id": "sg:person.0717016115.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717016115.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Xiangya School of Pharmaceutical Sciences, Central South University, 410008, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.216417.7", 
          "name": [
            "Xiangya School of Pharmaceutical Sciences, Central South University, 410008, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cao", 
        "givenName": "Dongsheng", 
        "id": "sg:person.0703125012.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703125012.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacy, The Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, China", 
          "id": "http://www.grid.ac/institutes/grid.452708.c", 
          "name": [
            "Department of Pharmacy, The Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cheng", 
        "givenName": "Yan", 
        "id": "sg:person.01042762205.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01042762205.91"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/s41401-018-0165-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107583546", 
          "https://doi.org/10.1038/s41401-018-0165-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2016.166", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020491005", 
          "https://doi.org/10.1038/onc.2016.166"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1362", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046070024", 
          "https://doi.org/10.1038/nrc1362"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2016.363", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010915352", 
          "https://doi.org/10.1038/onc.2016.363"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncb2152", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049008067", 
          "https://doi.org/10.1038/ncb2152"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-11-03", 
    "datePublishedReg": "2020-11-03", 
    "description": "Oncogenic activation of the mTOR signaling pathway occurs frequently in tumor cells and contributes to the devastating features of cancer, including breast cancer. mTOR inhibitors rapalogs are promising anticancer agents in clinical trials; however, rapalogs resistance remains an unresolved clinical challenge. Therefore, understanding the mechanisms by which cells become resistant to rapalogs may guide the development of successful mTOR-targeted cancer therapy. In this study, we found that eEF-2K, which is overexpressed in cancer cells and is required for survival of stressed cells, was involved in the negative-feedback activation of Akt and cytoprotective autophagy induction in breast cancer cells in response to mTOR inhibitors. Therefore, disruption of eEF-2K simultaneously abrogates the two critical resistance signaling pathways, sensitizing breast cancer cells to rapalogs. Importantly, we identified mitoxantrone, an admitted anticancer drug for a wide range of tumors, as a potential inhibitor of eEF-2K via a structure-based virtual screening strategy. We further demonstrated that mitoxantrone binds to eEF-2K and inhibits its activity, and the combination treatment of mitoxantrone and mTOR inhibitor resulted in significant synergistic cytotoxicity in breast cancer. In conclusion, we report that eEF-2K contributes to the activation of resistance signaling pathways of mTOR inhibitor, suggesting a novel strategy to enhance mTOR-targeted cancer therapy through combining mitoxantrone, an eEF-2K inhibitor.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/s41419-020-03153-x", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.8889072", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.8338972", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1042939", 
        "issn": [
          "2041-4889"
        ], 
        "name": "Cell Death & Disease", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "11"
      }
    ], 
    "keywords": [
      "breast cancer cells", 
      "mTOR inhibitors", 
      "cancer cells", 
      "breast cancer", 
      "significant synergistic cytotoxicity", 
      "cancer therapy", 
      "unresolved clinical challenge", 
      "eEF-2K inhibitor", 
      "rapalog resistance", 
      "negative feedback activation", 
      "eEF-2K", 
      "activation of Akt", 
      "clinical trials", 
      "clinical challenge", 
      "combination treatment", 
      "devastating features", 
      "synergistic cytotoxicity", 
      "structure-based virtual screening strategy", 
      "Combined treatment", 
      "mitoxantrone", 
      "tumor cells", 
      "K inhibitors", 
      "screening strategy", 
      "cancer", 
      "mTOR", 
      "therapy", 
      "anticancer agents", 
      "inhibitors", 
      "anticancer drugs", 
      "oncogenic activation", 
      "activation", 
      "rapalogs", 
      "Akt", 
      "cells", 
      "treatment", 
      "virtual screening strategy", 
      "pathway", 
      "novel strategy", 
      "potential inhibitors", 
      "tumors", 
      "trials", 
      "drugs", 
      "survival", 
      "resistance", 
      "induction", 
      "cytotoxicity", 
      "conclusion", 
      "agents", 
      "disruption", 
      "response", 
      "strategies", 
      "activity", 
      "study", 
      "mechanism", 
      "EEF", 
      "activation of resistance", 
      "development", 
      "features", 
      "challenges", 
      "wide range", 
      "range", 
      "critical resistance"
    ], 
    "name": "Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy", 
    "pagination": "948", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1132263726"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41419-020-03153-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33144562"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41419-020-03153-x", 
      "https://app.dimensions.ai/details/publication/pub.1132263726"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_850.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/s41419-020-03153-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41419-020-03153-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41419-020-03153-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41419-020-03153-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41419-020-03153-x'


 

This table displays all metadata directly associated to this object as RDF triples.

325 TRIPLES      21 PREDICATES      113 URIs      98 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41419-020-03153-x schema:about N02d390ead4e54e97a7be74f800a0e1c9
2 N0d4bc984c34a4f1e8b775cc3cc1a965f
3 N1db8920895e04c70b3f7244abe34f412
4 N2a1e2a843231464d9ed6495e3c7c3ef1
5 N3173f201e61147bf827599e7fea72702
6 N3a0038626ba34d53b6708ae41e4d7121
7 N439877aebd5d4ca39d1966127fe1c25b
8 N4752f1e9bcc34aba894e947f13cdf294
9 N496b2226c3ad449dbc822ad38023f3b6
10 N5607d6a5cf8f4cd18f99a12e2d0d341b
11 N56d0177e92364599b091f263233f61bf
12 N58354dcc6e094a68ac928628e9c5e8d7
13 N5bf8df46b54a42dab8ed3213258315c0
14 N8441e0b07e4a43b980823358b016135d
15 N9c1c7f34494a4dbfaeec6b6292f5030d
16 Nc3698316f55d41e5870df7eeca4fb184
17 Nec3e09570cee495e8810e92fedd1127c
18 Nf09dbc86440048d08968f1a35004529f
19 Nfe6d188a89644220abae5c578073208d
20 anzsrc-for:06
21 anzsrc-for:0601
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author N8f646c7184d449a387716c1e934d5024
25 schema:citation sg:pub.10.1038/ncb2152
26 sg:pub.10.1038/nrc1362
27 sg:pub.10.1038/onc.2016.166
28 sg:pub.10.1038/onc.2016.363
29 sg:pub.10.1038/s41401-018-0165-9
30 schema:datePublished 2020-11-03
31 schema:datePublishedReg 2020-11-03
32 schema:description Oncogenic activation of the mTOR signaling pathway occurs frequently in tumor cells and contributes to the devastating features of cancer, including breast cancer. mTOR inhibitors rapalogs are promising anticancer agents in clinical trials; however, rapalogs resistance remains an unresolved clinical challenge. Therefore, understanding the mechanisms by which cells become resistant to rapalogs may guide the development of successful mTOR-targeted cancer therapy. In this study, we found that eEF-2K, which is overexpressed in cancer cells and is required for survival of stressed cells, was involved in the negative-feedback activation of Akt and cytoprotective autophagy induction in breast cancer cells in response to mTOR inhibitors. Therefore, disruption of eEF-2K simultaneously abrogates the two critical resistance signaling pathways, sensitizing breast cancer cells to rapalogs. Importantly, we identified mitoxantrone, an admitted anticancer drug for a wide range of tumors, as a potential inhibitor of eEF-2K via a structure-based virtual screening strategy. We further demonstrated that mitoxantrone binds to eEF-2K and inhibits its activity, and the combination treatment of mitoxantrone and mTOR inhibitor resulted in significant synergistic cytotoxicity in breast cancer. In conclusion, we report that eEF-2K contributes to the activation of resistance signaling pathways of mTOR inhibitor, suggesting a novel strategy to enhance mTOR-targeted cancer therapy through combining mitoxantrone, an eEF-2K inhibitor.
33 schema:genre article
34 schema:isAccessibleForFree true
35 schema:isPartOf N944c3c8024f142049e2954a5d5a51023
36 Nd9c19c2669464a3da2d752bd20c91a66
37 sg:journal.1042939
38 schema:keywords Akt
39 Combined treatment
40 EEF
41 K inhibitors
42 activation
43 activation of Akt
44 activation of resistance
45 activity
46 agents
47 anticancer agents
48 anticancer drugs
49 breast cancer
50 breast cancer cells
51 cancer
52 cancer cells
53 cancer therapy
54 cells
55 challenges
56 clinical challenge
57 clinical trials
58 combination treatment
59 conclusion
60 critical resistance
61 cytotoxicity
62 devastating features
63 development
64 disruption
65 drugs
66 eEF-2K
67 eEF-2K inhibitor
68 features
69 induction
70 inhibitors
71 mTOR
72 mTOR inhibitors
73 mechanism
74 mitoxantrone
75 negative feedback activation
76 novel strategy
77 oncogenic activation
78 pathway
79 potential inhibitors
80 range
81 rapalog resistance
82 rapalogs
83 resistance
84 response
85 screening strategy
86 significant synergistic cytotoxicity
87 strategies
88 structure-based virtual screening strategy
89 study
90 survival
91 synergistic cytotoxicity
92 therapy
93 treatment
94 trials
95 tumor cells
96 tumors
97 unresolved clinical challenge
98 virtual screening strategy
99 wide range
100 schema:name Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy
101 schema:pagination 948
102 schema:productId N9a283156344540cf8eb93db276c4216b
103 N9af4f718553c46baa29f816c7f1f968e
104 Naa12e2ada5864f0fada240f0008f5b6d
105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1132263726
106 https://doi.org/10.1038/s41419-020-03153-x
107 schema:sdDatePublished 2022-11-24T21:04
108 schema:sdLicense https://scigraph.springernature.com/explorer/license/
109 schema:sdPublisher Na767b466347f46e991db622b8e1c4591
110 schema:url https://doi.org/10.1038/s41419-020-03153-x
111 sgo:license sg:explorer/license/
112 sgo:sdDataset articles
113 rdf:type schema:ScholarlyArticle
114 N0022037ee3b847a9aeb08ddbf6f8adce rdf:first sg:person.01266357307.80
115 rdf:rest N8ce50edb44fb47419c91074a89f3bd88
116 N02d390ead4e54e97a7be74f800a0e1c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Mice, Nude
118 rdf:type schema:DefinedTerm
119 N0d4bc984c34a4f1e8b775cc3cc1a965f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Protein Kinase Inhibitors
121 rdf:type schema:DefinedTerm
122 N1b71c0f907d0489d8a8ad35baaaeed54 rdf:first sg:person.01042762205.91
123 rdf:rest rdf:nil
124 N1db8920895e04c70b3f7244abe34f412 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Animals
126 rdf:type schema:DefinedTerm
127 N2a1e2a843231464d9ed6495e3c7c3ef1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Mitoxantrone
129 rdf:type schema:DefinedTerm
130 N315086dde35a49ddbb478540accf779e rdf:first sg:person.01203713300.51
131 rdf:rest Nb8cd2edcd6f24bdab44fee55e7033188
132 N3173f201e61147bf827599e7fea72702 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Gene Expression Regulation, Neoplastic
134 rdf:type schema:DefinedTerm
135 N3a0038626ba34d53b6708ae41e4d7121 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Mice
137 rdf:type schema:DefinedTerm
138 N439877aebd5d4ca39d1966127fe1c25b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Xenograft Model Antitumor Assays
140 rdf:type schema:DefinedTerm
141 N4752f1e9bcc34aba894e947f13cdf294 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Apoptosis
143 rdf:type schema:DefinedTerm
144 N496b2226c3ad449dbc822ad38023f3b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Elongation Factor 2 Kinase
146 rdf:type schema:DefinedTerm
147 N5607d6a5cf8f4cd18f99a12e2d0d341b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Proto-Oncogene Proteins c-akt
149 rdf:type schema:DefinedTerm
150 N56d0177e92364599b091f263233f61bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Antineoplastic Agents
152 rdf:type schema:DefinedTerm
153 N58354dcc6e094a68ac928628e9c5e8d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Drug Therapy, Combination
155 rdf:type schema:DefinedTerm
156 N5bf8df46b54a42dab8ed3213258315c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Cell Proliferation
158 rdf:type schema:DefinedTerm
159 N5f9a20493fe74cedad29f6616f896d8d rdf:first sg:person.010006343607.18
160 rdf:rest N315086dde35a49ddbb478540accf779e
161 N6341cf94ad284d33847f65e918f03490 rdf:first sg:person.015533713660.59
162 rdf:rest N0022037ee3b847a9aeb08ddbf6f8adce
163 N707cc231fbf7489b91a3afccd0699733 rdf:first sg:person.015312371350.79
164 rdf:rest N5f9a20493fe74cedad29f6616f896d8d
165 N8441e0b07e4a43b980823358b016135d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name TOR Serine-Threonine Kinases
167 rdf:type schema:DefinedTerm
168 N858de8a13bd4441e94ed4c7d9ea5bbcd rdf:first sg:person.0717016115.01
169 rdf:rest Ne0dc9a5825c340bd85369fc2e60a3053
170 N8ce50edb44fb47419c91074a89f3bd88 rdf:first sg:person.0755563621.60
171 rdf:rest Ndccf573ec5ed4231aba11b7e72603c31
172 N8f646c7184d449a387716c1e934d5024 rdf:first sg:person.07405203535.67
173 rdf:rest N707cc231fbf7489b91a3afccd0699733
174 N944c3c8024f142049e2954a5d5a51023 schema:volumeNumber 11
175 rdf:type schema:PublicationVolume
176 N9a283156344540cf8eb93db276c4216b schema:name doi
177 schema:value 10.1038/s41419-020-03153-x
178 rdf:type schema:PropertyValue
179 N9af4f718553c46baa29f816c7f1f968e schema:name pubmed_id
180 schema:value 33144562
181 rdf:type schema:PropertyValue
182 N9c1c7f34494a4dbfaeec6b6292f5030d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Humans
184 rdf:type schema:DefinedTerm
185 Na767b466347f46e991db622b8e1c4591 schema:name Springer Nature - SN SciGraph project
186 rdf:type schema:Organization
187 Naa12e2ada5864f0fada240f0008f5b6d schema:name dimensions_id
188 schema:value pub.1132263726
189 rdf:type schema:PropertyValue
190 Nb8cd2edcd6f24bdab44fee55e7033188 rdf:first sg:person.0660701641.51
191 rdf:rest N6341cf94ad284d33847f65e918f03490
192 Nc3698316f55d41e5870df7eeca4fb184 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Tumor Cells, Cultured
194 rdf:type schema:DefinedTerm
195 Nd9c19c2669464a3da2d752bd20c91a66 schema:issueNumber 11
196 rdf:type schema:PublicationIssue
197 Ndccf573ec5ed4231aba11b7e72603c31 rdf:first sg:person.0644067526.74
198 rdf:rest N858de8a13bd4441e94ed4c7d9ea5bbcd
199 Ne0dc9a5825c340bd85369fc2e60a3053 rdf:first sg:person.0703125012.75
200 rdf:rest N1b71c0f907d0489d8a8ad35baaaeed54
201 Nec3e09570cee495e8810e92fedd1127c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Female
203 rdf:type schema:DefinedTerm
204 Nf09dbc86440048d08968f1a35004529f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Autophagy
206 rdf:type schema:DefinedTerm
207 Nfe6d188a89644220abae5c578073208d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Breast Neoplasms
209 rdf:type schema:DefinedTerm
210 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
211 schema:name Biological Sciences
212 rdf:type schema:DefinedTerm
213 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
214 schema:name Biochemistry and Cell Biology
215 rdf:type schema:DefinedTerm
216 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
217 schema:name Medical and Health Sciences
218 rdf:type schema:DefinedTerm
219 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
220 schema:name Oncology and Carcinogenesis
221 rdf:type schema:DefinedTerm
222 sg:grant.8338972 http://pending.schema.org/fundedItem sg:pub.10.1038/s41419-020-03153-x
223 rdf:type schema:MonetaryGrant
224 sg:grant.8889072 http://pending.schema.org/fundedItem sg:pub.10.1038/s41419-020-03153-x
225 rdf:type schema:MonetaryGrant
226 sg:journal.1042939 schema:issn 2041-4889
227 schema:name Cell Death & Disease
228 schema:publisher Springer Nature
229 rdf:type schema:Periodical
230 sg:person.010006343607.18 schema:affiliation grid-institutes:grid.216417.7
231 schema:familyName Ye
232 schema:givenName Wenling
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010006343607.18
234 rdf:type schema:Person
235 sg:person.01042762205.91 schema:affiliation grid-institutes:grid.452708.c
236 schema:familyName Cheng
237 schema:givenName Yan
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01042762205.91
239 rdf:type schema:Person
240 sg:person.01203713300.51 schema:affiliation grid-institutes:grid.266539.d
241 schema:familyName Ren
242 schema:givenName Xingcong
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203713300.51
244 rdf:type schema:Person
245 sg:person.01266357307.80 schema:affiliation grid-institutes:grid.216417.7
246 schema:familyName Yin
247 schema:givenName Mingzhu
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266357307.80
249 rdf:type schema:Person
250 sg:person.015312371350.79 schema:affiliation grid-institutes:grid.452708.c
251 schema:familyName Jiang
252 schema:givenName Shilong
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015312371350.79
254 rdf:type schema:Person
255 sg:person.015533713660.59 schema:affiliation grid-institutes:grid.263761.7
256 schema:familyName Zhang
257 schema:givenName Yi
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015533713660.59
259 rdf:type schema:Person
260 sg:person.0644067526.74 schema:affiliation grid-institutes:grid.216417.7
261 schema:familyName Tao
262 schema:givenName Yongguang
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644067526.74
264 rdf:type schema:Person
265 sg:person.0660701641.51 schema:affiliation grid-institutes:grid.458489.c
266 schema:familyName Wang
267 schema:givenName Xinluan
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660701641.51
269 rdf:type schema:Person
270 sg:person.0703125012.75 schema:affiliation grid-institutes:grid.216417.7
271 schema:familyName Cao
272 schema:givenName Dongsheng
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703125012.75
274 rdf:type schema:Person
275 sg:person.0717016115.01 schema:affiliation grid-institutes:grid.266539.d
276 schema:familyName Yang
277 schema:givenName JinMing
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717016115.01
279 rdf:type schema:Person
280 sg:person.07405203535.67 schema:affiliation grid-institutes:grid.452708.c
281 schema:familyName Guan
282 schema:givenName Yidi
283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07405203535.67
284 rdf:type schema:Person
285 sg:person.0755563621.60 schema:affiliation grid-institutes:grid.216417.7
286 schema:familyName Wang
287 schema:givenName Kuansong
288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755563621.60
289 rdf:type schema:Person
290 sg:pub.10.1038/ncb2152 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049008067
291 https://doi.org/10.1038/ncb2152
292 rdf:type schema:CreativeWork
293 sg:pub.10.1038/nrc1362 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046070024
294 https://doi.org/10.1038/nrc1362
295 rdf:type schema:CreativeWork
296 sg:pub.10.1038/onc.2016.166 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020491005
297 https://doi.org/10.1038/onc.2016.166
298 rdf:type schema:CreativeWork
299 sg:pub.10.1038/onc.2016.363 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010915352
300 https://doi.org/10.1038/onc.2016.363
301 rdf:type schema:CreativeWork
302 sg:pub.10.1038/s41401-018-0165-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107583546
303 https://doi.org/10.1038/s41401-018-0165-9
304 rdf:type schema:CreativeWork
305 grid-institutes:grid.216417.7 schema:alternateName Cancer Research Institute, School of Basic Medicine, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Central South University, 410008, Changsha, Hunan, China
306 Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China
307 Department of Pathology, Xiangya Hospital, Central South University, 410078, Changsha, China
308 Xiangya School of Pharmaceutical Sciences, Central South University, 410008, Changsha, Hunan, China
309 schema:name Cancer Research Institute, School of Basic Medicine, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Central South University, 410008, Changsha, Hunan, China
310 Department of Dermatology, Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, 410008, Changsha, Hunan, China
311 Department of Pathology, Xiangya Hospital, Central South University, 410078, Changsha, China
312 Xiangya School of Pharmaceutical Sciences, Central South University, 410008, Changsha, Hunan, China
313 rdf:type schema:Organization
314 grid-institutes:grid.263761.7 schema:alternateName Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China
315 schema:name Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China
316 rdf:type schema:Organization
317 grid-institutes:grid.266539.d schema:alternateName Department of Cancer Biology and Toxicology, Department of Pharmacology, College of Medicine, Markey Cancer Center, University of Kentucky, 40536, Lexington, KY, USA
318 schema:name Department of Cancer Biology and Toxicology, Department of Pharmacology, College of Medicine, Markey Cancer Center, University of Kentucky, 40536, Lexington, KY, USA
319 rdf:type schema:Organization
320 grid-institutes:grid.452708.c schema:alternateName Department of Pharmacy, The Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, China
321 schema:name Department of Pharmacy, The Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, China
322 rdf:type schema:Organization
323 grid-institutes:grid.458489.c schema:alternateName Translational Medicine R&D Center, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, 518057, Shenzhen, China
324 schema:name Translational Medicine R&D Center, Institute of Biomedical and Health Engineering, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, 518057, Shenzhen, China
325 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...